NAMUR, Belgium, March 14, 2017 /PRNewswire/ -- VolitionRx Limited (NYSE MKT: VNRX) celebrated the company's recent announcement of a CE mark for its Nu.QTM Colorectal Cancer Screening Triage Test by ringing the closing bell at the New York Stock Exchange (NYSE) on Monday, March 13, 2017 at 4 p.m. U.S. Eastern Daylight Time (EDT). Volition received CE Marking on the Nu.QTM Colorectal Cancer Screening Triage Test in December 2016 and is currently marketing this novel blood test in Europe.
The event was preceded earlier that day by a more traditional bell ringing ceremony at Trinity Church Wall Street led by Volition's Chairman, Dr. Martin Faulkes. Dr. Faulkes, a keen bell ringer, donated and installed the 12 bells at Trinity Church Wall Street in 2006.
Speaking about the celebration, Cameron Reynolds, CEO of Volition said: "We are very pleased to be at the NYSE at this very exciting time for Volition. We are coming to market with a diagnostic cancer test that we believe meets a pressing and immediate need in many European countries. Being able to offer healthcare systems a simple and easy to use blood test, which may be used to triage FIT positive populations for colorectal cancer, has the potential to make a significant and positive difference for their national colorectal cancer screening programs."
An archive of the video for the New York Stock Exchange closing bell ceremony with Volition may be accessed at www.nyse.com/bell.
Scott Powell, Ph.D.
Executive Vice President
VolitionRx Ltd. (NYSE MKT: VNRX)
Office: +1 646-650-1351
Cell: +1 917-721-9480
Chief Marketing and Communications Officer VolitionRx
Mobile: +44 (0) 7557774620
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/volitionrx-limited-celebrates-ce-mark-announcement-by-ringing-closing-bell-at-the-new-york-stock-exchange-300423456.html
SOURCE VolitionRx Limited